Novartis AG ADR Stock
€113.50
Your prediction
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | -0.440% | 1.339% | 3.653% | 7.075% | 20.233% | 45.887% | 51.333% |
| Roche Holding AG ADR | 1.510% | 3.227% | 8.659% | 12.082% | 18.321% | -6.080% | 5.695% |
| Bayer AG ADR | -4.260% | -4.255% | -1.460% | -2.174% | 36.089% | -42.308% | -41.304% |
| Astrazeneca ADR | 0.680% | 3.497% | 6.475% | 4.225% | 15.625% | 29.825% | 59.483% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
2 Surefire Dividend Stocks to Buy for the Long Haul
Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research. Novartis AG (NYSE: NVS) is up
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
Shares in Arrowhead Pharmaceuticals (NASDAQ: ARWR) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned